Cargando…

Acquired BRAF gene fusions in Osimertinib resistant EGFR-mutant non-small cell lung cancer

Detalles Bibliográficos
Autores principales:	Rosell, Rafael, González-Cao, María, Codony-Servat, Jordi, Molina-Vila, Miguel Angel, de las Casas, Clara Mayo, Ito, Masaoki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080327/ https://www.ncbi.nlm.nih.gov/pubmed/37033354 http://dx.doi.org/10.21037/tcr-22-2888

Ejemplares similares

Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
por: Bracht, Jillian Wilhelmina Paulina, et al.
Publicado: (2019)

Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma
por: Ito, Masaoki, et al.
Publicado: (2019)

Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities
por: Rosell, Rafael, et al.
Publicado: (2021)

Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)
por: Codony-Servat, Carles, et al.
Publicado: (2017)

STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer
por: Attili, Ilaria, et al.
Publicado: (2018)

AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy
por: Bertran-Alamillo, Jordi, et al.
Publicado: (2019)

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
por: Jacobsen, Kirstine, et al.
Publicado: (2017)

Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
por: Lee, Jiyun, et al.
Publicado: (2022)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
por: Wang, Jiao‐Li, et al.
Publicado: (2022)

Src-Homology 2 Domain-Containing Phosphatase 2 in Resected EGFR Mutation-Positive Lung Adenocarcinoma
por: Ito, Masaoki, et al.
Publicado: (2020)

Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)
por: Karachaliou, Niki, et al.
Publicado: (2018)

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer
por: Roper, Nitin, et al.
Publicado: (2020)

Response to the Combination of Osimertinib, Dabrafenib, and Trametinib in Leptomeningitis From EGFR-Mutant NSCLC With Acquired BRAF V600E Mutation: A Case Report
por: Valet, Orion, et al.
Publicado: (2021)

Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells
por: Codony-Servat, Jordi, et al.
Publicado: (2020)

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
por: Zang, Hongjing, et al.
Publicado: (2020)

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis
por: Karachaliou, Niki, et al.
Publicado: (2018)

ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer
por: Hou, Helei, et al.
Publicado: (2021)

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
por: Karachaliou, Niki, et al.
Publicado: (2015)

Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
por: Ribeiro, Maurício Fernando Silva Almeida, et al.
Publicado: (2021)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
por: Chaib, Imane, et al.
Publicado: (2017)

Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
por: Karachaliou, Niki, et al.
Publicado: (2023)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Successful Treatment of EGFR-Mutant Synchronous SCLC and Lung Adenocarcinoma With Osimertinib
por: Batra, Ullas, et al.
Publicado: (2020)

Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2019)

Combined targeting of EGFR and BRAF triggers regression of osimertinib resistance by using osimertinib and vemurafenib concurrently in a patient with heterogeneity between different lesions
por: Sun, Mengyao, et al.
Publicado: (2021)

EGFR‐mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib
por: Hara, Reina, et al.
Publicado: (2021)

Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
por: Ye, Qiuyue, et al.
Publicado: (2023)

Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer
por: Aboubakar Nana, Frank, et al.
Publicado: (2021)

Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments
por: Denis, Marc G, et al.
Publicado: (2020)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
por: Ortega-Franco, Ana, et al.
Publicado: (2022)

SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer
por: Attili, Ilaria, et al.
Publicado: (2020)

Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation
por: Takamori, Shinkichi, et al.
Publicado: (2022)

Biological insights in non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Novel MRPL13-ALK and PPP1CB-ALK Double Fusion As a Potential Mechanism of Acquired Resistance to First-Line Osimertinib in EGFR-Mutant High-Grade Neuroendocrine Tumor of the Lung
por: Jiao, Yuyan, et al.
Publicado: (2020)

Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy
por: Kallergi, Galatea, et al.
Publicado: (2022)

Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice
por: Higuchi, Takashi, et al.
Publicado: (2019)

MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib
por: Nishiyama, Akihiro, et al.
Publicado: (2020)

Weekly osimertinib dosing prevents EGFR mutant tumor cells destined to home mouse lungs
por: Butle, Ashwin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3k8p66vfoeqj4vf7jhf087fk4a